SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

BioCardia Announces CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data To Be Presented At Heart Failure Society Of America Annual Meeting

Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today

Benzinga · 09/14/2022 07:02

Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that new data from its CardiAMP® Cell Therapy for Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), will be presented at the Heart Failure Society of America (HFSA) Annual Meeting on October 1, 2022 at 6:00pm titled, "Autologous Cell Therapy For HFrEF: Efficacy Outcomes at Two Years for The Roll-in Cohort of a Phase III Pivotal Trial." This year's HFSA meeting provides a hybrid format; in-person at the Gaylord National Harbor in Washington, D.C., or global live on-line access.